CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP

Julio C. Rojas, Jee Bang, Iryna V. Lobach, Richard M. Tsai, Gil D. Rabinovici, Bruce L. Miller, Adam L. Boxer

Research output: Contribution to journalArticle

Abstract

Objective To determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP). Methods We compared the ability of baseline CSF β-amyloid1-42, tau, phosphorylated tau 181 (p-tau), and neurofilament light chain (NfL) concentrations, measured by INNO-BIA AlzBio3 or ELISA, to predict 52-week changes in clinical (PSP Rating Scale [PSPRS] and Schwab and England Activities of Daily Living [SEADL]), neuropsychological, and regional brain volumes on MRI using linear mixed effects models controlled for age, sex, and baseline disease severity, and Fisher F density curves to compare effect sizes in 50 patients with PSP. Similar analyses were done using plasma NfL measured by single molecule arrays in 141 patients. Results Higher CSF NfL concentration predicted more rapid decline (biomarker × time interaction) over 52 weeks in PSPRS (p = 0.004, false discovery rate-corrected) and SEADL (p = 0.008), whereas lower baseline CSF p-tau predicted faster decline on PSPRS (p = 0.004). Higher CSF tau concentrations predicted faster decline by SEADL (p = 0.004). The CSF NfL/p-tau ratio was superior for predicting change in PSPRS, compared to p-tau (p = 0.003) or NfL (p = 0.001) alone. Higher NfL concentrations in CSF or blood were associated with greater superior cerebellar peduncle atrophy (fixed effect, p ≤ 0.029 and 0.008, respectively). Conclusions Both CSF p-tau and NfL correlate with disease severity and rate of disease progression in PSP. The inverse correlation of p-tau with disease severity suggests a potentially different mechanism of tau pathology in PSP as compared to Alzheimer disease.

Original languageEnglish (US)
Pages (from-to)E273-E281
JournalNeurology
Volume90
Issue number4
DOIs
StatePublished - Jan 23 2018

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP'. Together they form a unique fingerprint.

  • Cite this

    Rojas, J. C., Bang, J., Lobach, I. V., Tsai, R. M., Rabinovici, G. D., Miller, B. L., & Boxer, A. L. (2018). CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 90(4), E273-E281. https://doi.org/10.1212/WNL.0000000000004859